“Historically, pancreatic cancer has always been considered a dismal and depressing disease. Treatment options are limited; thus, we cannot offer patients as many therapies as we would like,” said Patel. “However, as we continue to enhance our knowledge and evaluate treatment strategies that have been utilized in other tumor types, we hope to discover new opportunities for our patients in the near future.” Read more . . .
As more is learned about nanoliposomal irinotecan (Onivyde), the safety and efficacy benefits of this approach over conventional chemotherapy have become more pronounced, according to Reema A. Patel, MD. She added that if the data continue to be positive, the agent has the potential to transform treatment in the frontline setting.